GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024

GRI Bio, Inc.

Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.
Cash and equivalents $4.1M as of March 31, 2024; public offering raised $5.5M gross in Feb 2024.
GRI-0621 Phase 2a biomarker study in IPF: interim data Q3 2024, topline results Q4 2024.
GRI-0803 for SLE: IND-enabling studies to complete Q3 2024; IND filing expected H2 2024.
Expanded IP estate with Korean patent issuance and Canadian notice of allowance for NKT cell modulators.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GRI Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $1.9 million.

Period: first quarter ended March 31, 2024
Net income: Net loss was $1.9 million
Result: reported results

Exact text from the filing

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

View on SEC.gov

Browse all earnings releases →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-24-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.